RAPT Therapeutics, Inc. (NASDAQ:RAPT) Major Shareholder Group Ii Lp Column Sells 21,738 Shares of Stock

RAPT Therapeutics, Inc. (NASDAQ:RAPT) major shareholder Group Ii Lp Column sold 21,738 shares of the firm’s stock in a transaction on Friday, September 10th. The stock was sold at an average price of $35.19, for a total transaction of $764,960.22. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Group Ii Lp Column also recently made the following trade(s):

  • On Monday, September 13th, Group Ii Lp Column sold 14,317 shares of RAPT Therapeutics stock. The stock was sold at an average price of $35.27, for a total transaction of $504,960.59.
  • On Monday, August 23rd, Group Ii Lp Column sold 68,340 shares of RAPT Therapeutics stock. The shares were sold at an average price of $31.34, for a total transaction of $2,141,775.60.
  • On Friday, August 20th, Group Ii Lp Column sold 4,539 shares of RAPT Therapeutics stock. The shares were sold at an average price of $30.08, for a total transaction of $136,533.12.

NASDAQ:RAPT opened at $37.18 on Wednesday. The company’s 50-day moving average price is $32.69 and its 200-day moving average price is $26.40. The company has a market cap of $1.10 billion, a P/E ratio of -15.43 and a beta of 0.04. RAPT Therapeutics, Inc. has a twelve month low of $14.63 and a twelve month high of $43.26.

RAPT Therapeutics (NASDAQ:RAPT) last issued its earnings results on Wednesday, August 11th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.05. RAPT Therapeutics had a negative net margin of 1,219.06% and a negative return on equity of 45.84%. As a group, analysts expect that RAPT Therapeutics, Inc. will post -2.64 earnings per share for the current year.

Several analysts recently commented on the stock. Roth Capital raised their price target on shares of RAPT Therapeutics from $38.00 to $72.00 and gave the company a “buy” rating in a research report on Monday, June 14th. Wells Fargo & Company raised their price target on shares of RAPT Therapeutics from $30.00 to $65.00 and gave the company an “overweight” rating in a research report on Monday, June 14th. Zacks Investment Research upgraded shares of RAPT Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 11th. Cantor Fitzgerald lifted their target price on shares of RAPT Therapeutics from $51.00 to $71.00 and gave the company an “overweight” rating in a research report on Monday, June 14th. Finally, SVB Leerink began coverage on shares of RAPT Therapeutics in a research report on Thursday, August 12th. They issued an “outperform” rating and a $49.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $59.86.

A number of hedge funds have recently modified their holdings of RAPT. Royal Bank of Canada raised its stake in shares of RAPT Therapeutics by 89.2% in the 2nd quarter. Royal Bank of Canada now owns 1,230 shares of the company’s stock valued at $39,000 after acquiring an additional 580 shares during the period. Ameritas Investment Partners Inc. raised its stake in shares of RAPT Therapeutics by 45.4% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,409 shares of the company’s stock valued at $45,000 after acquiring an additional 440 shares during the period. Citigroup Inc. raised its stake in shares of RAPT Therapeutics by 99.1% in the 2nd quarter. Citigroup Inc. now owns 2,714 shares of the company’s stock valued at $86,000 after acquiring an additional 1,351 shares during the period. Legal & General Group Plc raised its stake in shares of RAPT Therapeutics by 27.3% in the 2nd quarter. Legal & General Group Plc now owns 3,047 shares of the company’s stock valued at $96,000 after acquiring an additional 653 shares during the period. Finally, Metropolitan Life Insurance Co NY purchased a new stake in shares of RAPT Therapeutics in the 2nd quarter valued at approximately $169,000. 87.57% of the stock is currently owned by institutional investors.

RAPT Therapeutics Company Profile

Rapt Therapeutics, Inc operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.

Further Reading: What is the Beige Book?

Insider Buying and Selling by Quarter for RAPT Therapeutics (NASDAQ:RAPT)

Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.